Syd Hanna

Syd Hanna has a diverse work experience spanning over several companies and industries. In 2012, they became the Executive Director and Board Member of 30 Technology, a company focused on developing new models of care for medical conditions. Syd was also the Executive Director of various divisions within 30 Technology, including 30 Respiratory, 30 Therapeutics, 30 Dermatology, and 30 Animal Health, where they led research efforts in treating respiratory infections, neglected cutaneous diseases, dermatological conditions, and benefiting animal health, respectively. Prior to 30 Technology, Syd Hanna held the position of Executive Director at Edixomed Limited, where they oversaw the advancement of wound care treatments.

Outside of the healthcare industry, Syd Hanna served as a Director at OncoBioPharm Limited, an innovative biotechnology company focused on developing anti-cancer agents. Syd also held the position of Director at MedAnnex Limited, a biopharmaceutical company specializing in autoimmune disease treatments.

Prior to their roles in the biotechnology and healthcare sectors, Syd Hanna co-founded and served as Director of Elixir Ventures International and founded MGS, a company not further described. Syd also had previous experience as the Co-founder and Partner at Synergy Capital LLP, a co-founder of which they served from 2007 to 2011. Earlier in their career, they worked as a Hedge Fund Manager at Cheyne Capital and in Wholesale Capital Markets at Abbey National Treasury Services. Syd Hanna started their career as an Accountant at Abbey National.

Syd Hanna attended Ulster University from 1985 to 1987, where they pursued a BSc (Hons) in Finance. They did not obtain a degree in this field. Syd also holds additional certifications, including ACIB from the Chartered Institute of Banking & Finance - CIBF, ACMA from CIMA, and CGMA from CIMA. No information is provided regarding the specific months or years in which these certifications were obtained.